Lung-sparing total pleurectomy: the surgical option of choice in malignant pleural mesothelioma?

J Thorac Cardiovasc Surg 2008;135:620–26. [12] Lang-Lazdunski L, Bille A, Lal R, Cane P, McLean E, Landau D et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol 2012;7:737–43. [13] Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:1122–1128. [14] Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P, Members of IASLC Staging Committee. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2009;4:568–77. [15] Richards WG, Godleski JJ, Yeap BY, Corson JM, Chirieac LR, Zellos L et al. Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. Cancer 2010;116: 1510–7. [16] Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2012; 10.5858/ arpa.2012–0214-OA. [17] Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988;41:525–30. [18] Neumann V, Rutten A, Scharmach M, Muller KM, Fischer M. Factors influencing long-term survival in mesothelioma patients – results of the German mesothelioma register. Int Arch Occup Environ Health 2004;77:191–9. [19] Steele JP. Prognostic factors for mesothelioma. Hematol Oncol Clin North Am 2005;19:1041–52. [20] Wolf AS, Richards WG, Tilleman TR, Chirieac L, Hurwitz L, Bueno R et al. Characteristics of malignant pleural mesothelioma in women. Ann Thorac Surg 2010;90:949–56. [21] Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA et al. Estrogen receptor-β affects the prognosis of human malignant mesothelioma. Cancer Res 2009;69:4598–604. [22] Gordon GJ, Dong L, Yeap BY, Richards WG, Glickman JN, Edenfield H et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst 2009;101:678–86. [23] Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007–3013. [24] Nakas A, von Meyenfeldta E, Laua K, Muller S, Waller D. Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3–T4) non-sarcomatoid malignant pleural mesothelioma. Eur J Cardiothorac Surg 2012;41:1031–6. [25] Friedberg JS, Culligan MJ, Mick R, Stevenson J, Hahn SM, Sterman D et al. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg 2012;93:1658–67.